skip to Global Navigation Bar skip to main content


homeHome > About Us > Company Profile > History

 History

  • 2011~2014
  • 2001~2010
  • 1991~2000
  • 1981~1990
  • 1945~1980
2011~2013 history
2015
  • › Received AA-grade in CP(Compliance Program) evaluation (organized by KFTC(Korea Fair Trade Commission))
2014
  • › 'NABOTA': Selected as 'World's First-Class Product', Korea Trade-Investment Promotion Agency(KOTRA)
  • › Completed registration of 6 items such as Urusa, EZN6, Bearse, Albis Tab, etc., in Georgia
  • › Signed an MOU with the Institute of Physical and Chemical Research(RIKEN) of Japan for new drug development
  • › Established Daewoong Pharmaceutical Liaoning Research Institute in China
  • › 'Suglat': Co-Promotion Agreement signed with Astellas Pharma Korea
  • › Entered into strategic alliance with Takeda Pharmaceuticals Korea for DAXAS
  • › Award the prize, "the Most Trusted Company of Korea"(organized by Korea CEO Association)
  • › Entered into strategic alliance with Sandoz Korea for 'Sandoz Zoledronic acid Injection'
  • › Expanded into Philippines market with 'Caretropin'(growth hormone)
  • › Launched 'Easyderm Foam'(foam formulation wet dressing)
  • › Acquired 'AA-' corporate credit rating
  • › Daewoong signed 3-party MOU with CGBio and VANCIVE
  • › 'Nabota', the botulinum toxin solution, approved in Thailand
  • › Signed the agreement to export 'Caretropin', the growth hormones, to Georgia, the Dominican Republic, and Hong Kong
  • › Launch of Compliance Team(committed to ensuring fair trade)
  • › Contract with Daiichi Sankyo Korea to launch co-promotion of 'Olostar'(Complex incrementally modified drug(IMD)
  • › 'Nabota'(Botulinum toxin): Launched in Korea
  • › 'Imatinib'(Drug for Treatment of chronic myelogenous leukemia): Export Agreement Signed with Arian Salamat Sina for Iran
  • › 'Olostar'(Complex incrementally modified drug(IMD) of Olmesartan and Rosuvastatin): Launched in Korea
  • › Contract to Put 'Sitavig''(Medicine for the treatment of herpes labialis)onto domestic market
  • › 'Elidel'(Non-steroidal drug for atopic dermatitis): Launched in Korea
  • › 'Easyderm Beauty' (Spot-type wet dressing for treating the skin troubles): Launched in Korea
  • › 'Medi-well diabetes diet' (Nutritious food for diabetic patients): Launched in Korea
  • › Received technology export prize from Korea New Drug Development Award
  • › 'Nabota'(Botulinum toxin): Sales Agreement Signed with Bago for Argentina
  • › NOVOSET (Calcium phosphate ceramic bone cement medical device): Launched in Korea.
2013
  • › 'Export Agreement signed with Snimed(Azerbaijan) and Eczamed(Georgia)
       for the following products: URSA, Bearse, Albis, EZN 6 Pro, and more.
  • › 'Nabota'(Botulinum toxin): Sales Agreement Signed with TKJ for Iran
  • › 'Nabota'(Botulinum toxin): Sales Agreement Signed with Pharmavital for 15 countries in Latin America
  • › Received two grand prizes from '2013 Web Award Korea' (Web Magazine & Mobile Web)
  • › Designated as a 'Family Friendly Management company'
  • › 'Nabota'(Botulinum toxin): Export Agreement Signed with Evolus for U.S.
  • › 'URSA, Eposis(EPO), Tobra Opthalmic Solution': Export Agreement Signed with Asia-Pharma for Mongolia
  • › Received '2013 Innovative Pharmaceutical Company Award'
  • › 'EZN6 Eve'(Liquid analgesic relieving menstrual cramps): Launched in Korea
  • › 'Alitoc' (Oral tablet for hand eczema treatment): Launched in Korea
  • › Acquistion Agreement signed with Baifeng (China)
  • › 'UK Injection KIT' Co-Promotion Agreement signed with UK Chemipharm Co., Ltd.
  • › 'EasyDerm Plus Thin' (hydrocolloid dressing): Launched in Korea
  • › 'EasyDerm Plus Band' (hydrocolloid dressing): Launched in Korea
  • › 'Caretropin' (pen injector): Completed the utility model right registration in Russia
  • › 'Risen Plus' (Osteoporosis treatment): Launched in Korea
  • › 'Smecta Suspension': Export Agreement Signed for China
  • › Luphere Depot Inj (GnRH-Agonist): Export Agreement signed with Pharm-Sintez for Russia.
  • › Novosis-Dent (Novel concept bio-fusion medical device): Launched in Korea.
  • › ‘URSA’: Selected as the No. 1 preferred supplement by major companies’ CEOs for 2 consecutive years.
  • › Contract to export 'Easyef Topical Solution' and 'EPOSIS Prefilled Syringe INJ' to Turkey.
2012
  • › ‘Anturol’ (gel-type treatment for overactive bladder): Licensed-In
  • › Caretropine pen : Awarded as ‘2011~2012 World Star’
  • › ‘Neovist’ (CT Contrast Medium): Export Agreement signed for Iran and Ukraine.
  • › ‘Eklira’ (COPD treatment): Licensed-In
  • › ‘Bearse’ (digestive enzyme): Export Agreement signed for China.
  • › URSA, official sponsor agreement signed for ‘K-League 2012’.
  • › Alzheimer’s Treatment, selected for the government-funded new drug development project
  • › Selected as ‘World-class 300’, the global corporation establishment project.
  • › Agreement signed for Venture Company (medical product) establishment in Indonesia.
  • › Move (health functional food for joints): Launched in Korea.
  • › ‘Nurigra’ (erectile dysfunction treatment): Launched in Korea.
  • › ‘FOISTAR’(Serine protease inhibitor.): Launched in Korea
  • › Selected as ‘Innovative Pharmaceutical Corporation’
  • › Received ‘2012 Excellent Technology Award’
  • › ‘Instanyl’ (cancer pain treatment): License-In
  • › ‘EasyDerm Plus’ (hydrocolloid dressing): Launched in Korea.
  • › ‘Easyef’ (diabetic ulcer treatment): Export Agreement signed for 11 countries.
  • › ‘Neovist’ (CT Contrast Medium): Export Agreement signed for 3 countries in Eastern Europe.
  • › ‘Daewoong Primidone’ (orphan drug for Epilepsy): Relaunched in Korea.
  • › ‘Easyef’: Export Agreement signed with EGY-TEC for Egypt.
  • › ‘URSA’: Export Agreement signed with LUPIN Ltd, for Australia and New Zealand.
  • › ‘Supect’ (the first CML treatment in Asia): Launched in Korea.
2011
  • › Establishment of very first nursery facility for employees in the industry.
  • › Daewoong Bio’s cGMP factory completed in Bal-An.
  • › Phase 2 Clinical Trial approved for neuropathic pain treatment.
  • › ‘Bearprexa’ (schizophrenic treatment): Launched in Korea.
  • › ‘Bearprofen’ (fever relief syrup): Launched in Korea.
  • › 'Vytorin’: Co-Promotion Agreement signed with MSD Korea.
  • › ‘Symbicort’: Co-Promotion Agreement signed with AstraZeneca Korea.
  • › Pen injector, awarded prize of the Minister of Knowledge Economy
  • › GH (Goods of Health) acquired for ‘URSA’ and ‘Albis’ for their excellent quality.
  • › 17 million(KRW) Export agreement signed for the Middle East.
  • › Entered into Contrast Medium market.
  • › ‘Newlanta’: Approved in China
  • › URSA TV Commercial: Awarded as ‘Best Commercial Selected by College Students’.
  • › ‘URSA Man’ (Du-Ri Cha), selected as the best commercial model for 2011.
  • › ‘Family-Friendly Industry’ Title: expanded to end of 2013.